Formal discussant of the TRINOVA-1 presentation, Antonio Casado, MD, Hospital Universitario San Carlos, Madrid, said that the study showed a clinically meaningful benefit with the addition of trebananib in this pretreated group of patients with recurrent epithelial ovarian cancer. Also, the drug had a good side-effect profile.
Moving forward, if future trials of trebananib support these results and the drug is approved, the question will be how to combine it and sequence it with currently available therapies, he noted.
“Weekly paclitaxel and trebananib could be an option in patients who show disease progression within 12 months after one to three previous lines of therapy,” Dr. Casado said. ■
Disclosure: Dr. Casado reported no potential conflicts of interest.
Trebananib, an investigational antiangiogenesis inhibitor with a different mechanism of action than bevacizumab (Avastin), significantly improved progression-free survival in recurrent platinum-resistant and partially platinum-sensitive ovarian cancer in the phase III TRINOVA-1 trial. The addition...